Sarcomatoid melanoma is an extremely rare pattern of malignant melanoma, and only few cases have been described throughout the literature. We herein report a case of a patient with newly diagnosed, metastatic giant sarcomatoid melanoma of the arm. The patient underwent surgical removal of the huge mass, and NGS sequencing demonstrated BRAF V600E mutation. In view of histological, immunohistochemical and molecular findings, a combined BRAF/MEK inhibitor (BRAF/MEK-i) therapy was prescribed as first line treatment. A complete response (over one year) to targeted therapy was obtained, and no adverse events have been reported. The patient maintained a full range of shoulder and elbow movements, and she is able to live independently and resume her daily activities. We therefore recommend that all patients with undifferentiated melanomas, sarcomatoid cutaneous malignancies or other mesenchymal tumours, should undergo BRAFV600E mutation testing.
A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: a complete response to targeted therapy / Torresetti, Matteo; Brancorsini, Donatella; Morgese, Francesca; Cognigni, Valeria; Scalise, Alessandro; Berardi, Rossana; Di Benedetto, Giovanni. - In: ONCOTARGET. - ISSN 1949-2553. - 11:34(2020), pp. 3256-3262-3262. [10.18632/oncotarget.27701]
A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: a complete response to targeted therapy
Torresetti, Matteo
;Cognigni, Valeria;Scalise, Alessandro;Berardi, Rossana;Di Benedetto, Giovanni
2020-01-01
Abstract
Sarcomatoid melanoma is an extremely rare pattern of malignant melanoma, and only few cases have been described throughout the literature. We herein report a case of a patient with newly diagnosed, metastatic giant sarcomatoid melanoma of the arm. The patient underwent surgical removal of the huge mass, and NGS sequencing demonstrated BRAF V600E mutation. In view of histological, immunohistochemical and molecular findings, a combined BRAF/MEK inhibitor (BRAF/MEK-i) therapy was prescribed as first line treatment. A complete response (over one year) to targeted therapy was obtained, and no adverse events have been reported. The patient maintained a full range of shoulder and elbow movements, and she is able to live independently and resume her daily activities. We therefore recommend that all patients with undifferentiated melanomas, sarcomatoid cutaneous malignancies or other mesenchymal tumours, should undergo BRAFV600E mutation testing.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.